Skip to main content
. Author manuscript; available in PMC: 2018 Apr 12.
Published in final edited form as: ACS Appl Mater Interfaces. 2017 Mar 28;9(14):12195–12202. doi: 10.1021/acsami.6b15987

Figure 5.

Figure 5

Cell viability after incubation with protein corona formulations. Fulvestrant colloids targeted with a trastuzumab corona reduce cell viability. BT-474 cells were exposed to 50 μM fulvestrant formulations with trastuzumab or IgG (3.5 μM) for 24 h followed by fresh media for an additional 48 h. All formulations used were 50 μM fulvestrant with 1% DMSO in 5% serum. Cell viability is represented as a percentage of 1% DMSO vehicle control. *, p < 0.05; **, p < 0.01. (n = 4 biological replicates; mean ± SD).